287 related articles for article (PubMed ID: 8765521)
1. Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo.
Shi DF; Bradshaw TD; Wrigley S; McCall CJ; Lelieveld P; Fichtner I; Stevens MF
J Med Chem; 1996 Aug; 39(17):3375-84. PubMed ID: 8765521
[TBL] [Abstract][Full Text] [Related]
2. Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
Mortimer CG; Wells G; Crochard JP; Stone EL; Bradshaw TD; Stevens MF; Westwell AD
J Med Chem; 2006 Jan; 49(1):179-85. PubMed ID: 16392802
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648).
Aiello S; Wells G; Stone EL; Kadri H; Bazzi R; Bell DR; Stevens MF; Matthews CS; Bradshaw TD; Westwell AD
J Med Chem; 2008 Aug; 51(16):5135-9. PubMed ID: 18666770
[TBL] [Abstract][Full Text] [Related]
4. Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
Chua MS; Shi DF; Wrigley S; Bradshaw TD; Hutchinson I; Shaw PN; Barrett DA; Stanley LA; Stevens MF
J Med Chem; 1999 Feb; 42(3):381-92. PubMed ID: 9986708
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Re and (99m)Tc complexes of 2-(4'-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals.
Tzanopoulou S; Sagnou M; Paravatou-Petsotas M; Gourni E; Loudos G; Xanthopoulos S; Lafkas D; Kiaris H; Varvarigou A; Pirmettis IC; Papadopoulos M; Pelecanou M
J Med Chem; 2010 Jun; 53(12):4633-41. PubMed ID: 20518489
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives.
Abdelgawad MA; Belal A; Omar HA; Hegazy L; Rateb ME
Arch Pharm (Weinheim); 2013 Jul; 346(7):534-41. PubMed ID: 23740859
[TBL] [Abstract][Full Text] [Related]
8. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity.
Solomon VR; Hu C; Lee H
Bioorg Med Chem; 2009 Nov; 17(21):7585-92. PubMed ID: 19804979
[TBL] [Abstract][Full Text] [Related]
9. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
10. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of potent antitumor 5,4'-diaminoflavone derivatives based on metabolic considerations.
Akama T; Ishida H; Shida Y; Kimura U; Gomi K; Saito H; Fuse E; Kobayashi S; Yoda N; Kasai M
J Med Chem; 1997 Jun; 40(12):1894-900. PubMed ID: 9191967
[TBL] [Abstract][Full Text] [Related]
12. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
Bradshaw TD; Wrigley S; Shi DF; Schultz RJ; Paull KD; Stevens MF
Br J Cancer; 1998 Mar; 77(5):745-52. PubMed ID: 9514053
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).
Bradshaw TD; Chua MS; Orr S; Matthews CS; Stevens MF
Br J Cancer; 2000 Jul; 83(2):270-7. PubMed ID: 10901382
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity of novel rhodacyanine dyes as antitumor agents.
Kawakami M; Koya K; Ukai T; Tatsuta N; Ikegawa A; Ogawa K; Shishido T; Chen LB
J Med Chem; 1998 Jan; 41(1):130-42. PubMed ID: 9438030
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles.
Huang ST; Hsei IJ; Chen C
Bioorg Med Chem; 2006 Sep; 14(17):6106-19. PubMed ID: 16714116
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo.
Stojkovic R; Karminski-Zamola G; Racane L; Tralic-Kulenovic V; Glavas-Obrovac L; Ivankovic S; Radacic M
Methods Find Exp Clin Pharmacol; 2006; 28(6):347-54. PubMed ID: 16894403
[TBL] [Abstract][Full Text] [Related]
17. 3-methyl-2-(4-substituted phenyl)-4,5-dihydronaphtho[1,2-c]-pyrazoles: synthesis and in-vitro biological evaluation as antitumour agents.
Al-Saadi MS; Rostom SA; Faidallah HM
Arch Pharm (Weinheim); 2008 Mar; 341(3):181-90. PubMed ID: 18214843
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
20. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds.
Bradshaw TD; Stevens MF; Westwell AD
Curr Med Chem; 2001 Feb; 8(2):203-10. PubMed ID: 11172675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
